Trial Profile
XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Ischaemic heart disorders
- Focus Adverse reactions
- Acronyms XIENCE Xpedition SV Japan PMS
- Sponsors Abbott Vascular
- 20 Apr 2021 Status changed from active, no longer recruiting to completed.
- 25 Sep 2018 Results of a pooled analysis from XIENCEV USA, XIENCEV Japan, XIENCE V China and XIENCE V India trials presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 11 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2021.